1234

Interferons in the treatment of myeloproliferative neoplasms

The MPNAA has just become aware of this extensive article about interferon, written by US haematologists and published in 2024 in Therapeutic Advances in Hematology. As so many more MPN patients are now being treated with interferon, we have copied the abstract as well as a link to the full article…
Read more

PBAC has recommended ruxolitinib be listed on the PBS for PV

We are thrilled to advise that the Pharmaceutical Benefits Committee (PBAC) at its March meeting has recommended that ruxolitinib (jakavi) be listed on the Pharmaceutical Benefits Scheme (PBS) for adult polycythemia vera patients who are resistant to or intolerant of hydroxycarbamide (hydroxyurea). This…
Read more

Momelotinib (OMJJARA) now on PBS

The MPN AA is delighted to advise that the Australian government has now approved the inclusion of momelotinib, now known as OMJJARA, onto the Pharmaceutical Benefits Scheme (PBS). Momelotinib was originally developed in Melbourne.  A short news item about its approval is HERE. What is momelotinib…
Read more

International review series on MPNs published

The April 2025 edition of Haematologica features an excellent review series on MPNs. The authors of the introduction paper to the series, Australia's Drs Steven Lane and Yin Yuan, explain that 'the review series is not designed to be a definitive review of all aspects of MPN biology and treatment.…
Read more

PV treatment ‘rusfertide’ trial results

Early results from the Phase 3 clinical trial of the hepciden mimetic 'rusfertide' have recently been published. Rusfertide aims to overcome the need for phlebotomy in patients with polycythemia vera (PV), by keeping haematocrit below .45. Early phase 3 trial results show that rusfertide was well…
Read more

Pegasys shortage update: where to from here

The Therapeutic Goods Administration has updated its advice on a possible shortage of Pegasys in Australia. Its website now states that there is an anticipated shortage from June to September 2025. To date, prompt action by the supplier of Pegasys in Australia, Echo Therapeutics in partnership with…
Read more

Welcome to the MPN Alliance Australia website.

MPN stands for Myeloproliferative Neoplasms which are a group of rare chronic blood cancers.

The MPN Alliance Australia, (MPN AA) is run by MPN patients for MPN patients and their families. We all give of our time voluntarily.

MPN patient quality of life is central to everything we do. We aim for these pages to assist patients and families to find support and relevant up to date information related to myeloproliferative neoplasms. This site acts as a portal to comprehensive evidence-based disease information.

We also provide external links to disease-specific articles and other information from Australian and international researchers and clinicians, and MPN organisations.

We welcome your feedback as we aim to support you as best we can. Please send us a message if you would like to share ideas with us to improve our site.

Share to:
Translate »